Online inquiry

IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14079MR)

This product GTTS-WQ14079MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets DLL4 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_019074.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567
UniProt ID Q9NR61
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14079MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9323MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ506MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 47H4
GTTS-WQ5057MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CaCP-29
GTTS-WQ9608MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ271MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 17-1A
GTTS-WQ1567MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ13199MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ7620MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEN1029
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW